---
document_datetime: 2023-09-21 20:50:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/artesunate-amivas-epar-all-authorised-presentations_en.pdf
document_name: artesunate-amivas-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7528124
conversion_datetime: 2025-12-20 09:56:46.730046
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex 3

| MA(EU) number    | (Invented) name     | Strength   | Pharmaceutical Form                           | Route of Administration   | Immediate Packaging                         | Content (concentration)        | Pack size         |
|------------------|---------------------|------------|-----------------------------------------------|---------------------------|---------------------------------------------|--------------------------------|-------------------|
| EU/1/21/1582/001 | Artesunate - Amivas | 110 mg     | Powder and solvent for solution for injection | Intravenous use           | Powder: vial (glass); Solvent: vial (glass) | Powder: 110 mg; Solvent: 12 ml | 2 vials + 2 vials |
| EU/1/21/1582/002 | Artesunate - Amivas | 110 mg     | Powder and solvent for solution for injection | Intravenous use           | Powder: vial (glass); Solvent: vial (glass) | Powder: 110 mg; Solvent: 12 ml | 4 vials + 4 vials |